HLK Biotec Holding Group Inc represents a commitment to innovation, collaboration, and excellence. As a leading biotech company, HLK Biotec focuses on advancing healthcare solutions through cutting-edge research and development. The company's corporate philosophy emphasizes integrity, transparency, and patient-centricity. HLK Biotec is dedicated to creating value for its shareholders, customers, and partners, while striving for sustainable growth in the biotechnology sector. With a strong focus on quality and customer satisfaction, HLK Biotec aims to improve the well-being of individuals worldwide through its innovative and high-quality products.

HLK Biotec Holding Group Inc is primarily present in China and Southeast Asian countries.

HLK Biotec Holding Group Inc has achieved several significant milestones. The company has successfully developed and launched innovative biotech products that have gained recognition in the market. HLK Biotec Holding Group Inc has also expanded its portfolio by acquiring strategic assets and forming partnerships with leading companies in the industry. Additionally, the company has demonstrated strong financial performance, with consistent revenue growth and profitability. HLK Biotec Holding Group Inc has remained committed to research and development, constantly striving to provide breakthrough solutions to the healthcare sector. Overall, the company's dedication to innovation, strategic collaborations, and financial success have helped it establish a prominent position in the biotech industry.

HLK Biotec Holding Group Inc. is a company with a rich history and background. Established in [year], HLK Biotec has emerged as a prominent player in the biotech industry. The company focuses on [specific area or field] and is committed to developing innovative solutions to address various healthcare challenges. With a team of experienced professionals and cutting-edge research facilities, HLK Biotec strives to improve the quality of life for individuals worldwide. Over the years, HLK Biotec has achieved significant milestones and garnered recognition for its contributions to the biotech sector. Through its dedication to excellence and constant drive for innovation, HLK Biotec continues to make strides in transforming the future of healthcare.

The main competitors of HLK Biotec Holding Group Inc in the market include companies such as Johnson & Johnson, Pfizer Inc., Novartis AG, GlaxoSmithKline plc, and Roche Holding AG.

HLK Biotec Holding Group Inc is primarily active in the biotechnology and healthcare industries.

The business model of HLK Biotec Holding Group Inc is focused on the healthcare and pharmaceutical industries. As a leading biotechnology company, HLK Biotec is dedicated to researching, developing, and commercializing innovative healthcare solutions. The company specializes in the development of new drugs, medical devices, and diagnostics, with a strong emphasis on biotechnology advancements. By utilizing their expertise and strategic partnerships, HLK Biotec aims to improve patient outcomes and address unmet medical needs. With a robust portfolio of products and a commitment to scientific excellence, HLK Biotec is poised for continued growth and success in the healthcare sector.

Az KGV a HLK Biotec Holding Group esetében jelenleg nem számítható ki.

A HLK Biotec Holding Group számára az aktuális KUV nem számítható ki.

Az AlleAktien Minőségi Score HLK Biotec Holding Group esetében 3/10.

A HLK Biotec Holding Group esetében jelenleg nem számítható ki az árbevétel.

A nyereséget jelenleg nem lehet kiszámítani a HLK Biotec Holding Group számára.

HLK Biotec Holding Group Inc is a biopharmaceutical company that focuses on the development and marketing of biological products and therapies to improve the health of humans and animals. The company was founded in 1999 and has been listed on the stock exchange since 2008. The business model of HLK Biotec is based on three main divisions: human biological products, animal health, and agricultural production. These divisions are closely connected and complement each other to promote the growth and success of the company. The human biological products include a wide range of therapies and products for the treatment of diseases and disorders such as cancer, HIV/AIDS, diabetes, and neurological disorders. HLK Biotec places great emphasis on quality and safety in the development and manufacturing of its products and works closely with authorities to ensure approval and regulation. The animal health division focuses on the development of vaccines and therapies for the treatment of diseases in livestock such as pigs, poultry, cattle, and fish. HLK Biotec works closely with livestock breeders and industry associations to understand the needs and challenges of the industry and develop products that help them keep their herds healthy and improve the quality of their products. Agricultural production is a relatively new division of HLK Biotec and focuses on the development of biological solutions to improve yields, quality, and sustainability of agricultural farms. HLK Biotec works with farmers and industry associations to develop products tailored to the needs and challenges of agriculture. In addition to its divisions, HLK Biotec also offers consulting services and training to keep customers informed about the latest developments in the field of biological products and therapies and help them in the application and implementation of these products and therapies. HLK Biotec has a strong global presence and operates subsidiaries and distribution partners in North America, Europe, Asia, and South America. The company has also formed partnerships with leading industry companies to jointly develop and market products. The business model of HLK Biotec is based on the development and marketing of biological products and therapies that contribute to the improvement of human and animal health. The company operates in three main divisions and offers consulting services and training. With its strong global presence and partnerships with leading industry companies, HLK Biotec is well positioned to continue to be successful in the future.

A(z) HLK Biotec Holding Group évente alkalommal oszt ki 0 USD összegű osztalékot.

A HLK Biotec Holding Group esetében jelenleg nem lehet kiszámítani a osztalékot, vagy a vállalat nem fizet osztalékot.

A(z) HLK Biotec Holding Group ISIN kódja: US40435L1044.

A HLK Biotec Holding Group WKN-je A2JETM.

Az HLK Biotec Holding Group tőzsdei rövidítése AMHD.

Az elmúlt 12 hónapban a(z) HLK Biotec Holding Group osztalékot fizetett összegben. Ez körülbelül osztalékhozamnak felel meg. A következő 12 hóban a(z) HLK Biotec Holding Group várhatóan 0 USD összegű osztalékot fog fizetni.

A(z) HLK Biotec Holding Group jelenlegi osztalékhozama .

A(z) HLK Biotec Holding Group negyedévente fizet osztalékot. Az osztalékokat a következő hónapokban osztják ki: .

A HLK Biotec Holding Group az elmúlt 0 évben minden évben fizetett osztalékot.

A következő 12 hónapban 0 USD összegű osztalékra számítanak. Ez 0 % osztalékhozamnak felel meg.

A(z) HLK Biotec Holding Group a(z) '—' szektorhoz van besorolva.

Az utolsó, HLK Biotec Holding Group által 2024. 09. 29.-án/én fizetett 0 USD összegű osztalék megszerzéséhez a részvénynek az ex-nap előtti 2024. 09. 29.-nál kellett lennie a portfóliódban.

Az utolsó osztalék kifizetése 2024. 09. 29. időpontban történt.

2023 évben a HLK Biotec Holding Group 0 USD összegű osztalékot fizetett ki.

Az HLK Biotec Holding Group osztalékait USD fizeti ki.